Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC)

Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. 2004.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.